

MusclePharm Corp  
Form 8-K  
May 26, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**May 26, 2016**

**Date of report (date of earliest event reported)**

**MusclePharm Corporation**

**(Exact name of registrant as specified in its charter)**

|   |                     |                       |
|---|---------------------|-----------------------|
| <b>Nevada</b>                           | <b>000-53166</b>    | <b>77-0664193</b>     |
| <b>(State or other jurisdictions of</b> | <b>(Commission</b>  | <b>(I.R.S.</b>        |
| <b>incorporation or organization)</b>   | <b>File Number)</b> | <b>Employer</b>       |
|   |                     | <b>Identification</b> |
|   |                     | <b>Nos.)</b>          |

**4721 Ironton Street, Building A**

**Denver, Colorado 80239**

**(Address of principal executive offices) (Zip Code)**

**(303) 396-6100**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On May 26, 2016, the Company issued a press release announcing an update to its restructuring plan.

A copy of the press release is attached hereto as Exhibit 99.1

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits:**

| Exhibit No. | Description   |
|-------------|---|
| 99.1        | Press Release of MusclePharm Corporation, dated May 26, 2016. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MUSCLEPHARM  
CORPORATION**

By: /s/ John Price  
Name: John Price  
Title: Chief  
Financial Officer

Date: May 26, 2016

**EXHIBIT INDEX**

Exhibit No. Description

99.1 Press Release of MusclePharm Corporation, dated May 26, 2016.